Raloxifene

Overview

Raloxifene is a second-generation selective estrogen receptor modulator (SERM) belonging to the benzothiophene chemical class. Developed by Eli Lilly and marketed under the brand name Evista, it was first approved by the FDA in 1997 for the prevention and treatment of postmenopausal osteoporosis. In 2007, it received an additional indication for the reduction of invasive breast cancer risk in postmenopausal women with osteoporosis or at high risk for breast cancer.

Raloxifene represents a significant advancement in SERM pharmacology because it demonstrates tissue-selective estrogenic and anti-estrogenic activity with a more favorable side effect profile than tamoxifen in certain respects. In bone tissue, raloxifene acts as an estrogen agonist, preserving bone mineral density and reducing fracture risk. In breast and uterine tissue, it acts as an estrogen antagonist, reducing breast cancer incidence without stimulating endometrial proliferation. This tissue selectivity arises from the differential recruitment of coactivator and corepressor proteins to the estrogen receptor complex in different cell types.

The development of raloxifene was informed by the observation that the ideal SERM would preserve the beneficial skeletal and cardiovascular effects of estrogen while antagonizing its proliferative effects in breast and uterine tissue. While raloxifene has achieved the first two objectives, its cardiovascular effects have proven more complex, as demonstrated by the results of the RUTH (Raloxifene Use for The Heart) trial.

Mechanism of Action

Raloxifene binds to both estrogen receptor alpha (ERa) and estrogen receptor beta (ERb) with high affinity. However, unlike estradiol, raloxifene induces a distinct conformational change in the ligand-binding domain of the receptor that alters the recruitment of transcriptional coregulatory proteins in a tissue-specific manner.

Structural Basis of Tissue Selectivity

X-ray crystallographic studies have revealed that when raloxifene binds to ERa, the position of helix 12 in the ligand-binding domain differs from its position when estradiol occupies the receptor. Specifically, the bulky side chain of raloxifene sterically prevents helix 12 from adopting the agonist conformation necessary for efficient recruitment of coactivator proteins containing LXXLL motifs (such as SRC-1, SRC-2, and SRC-3). Instead, the receptor adopts a conformation that favors recruitment of corepressor proteins (NCoR, SMRT) in tissues where these corepressors are abundant, while still permitting partial agonist activity in tissues where certain coactivators predominate.

Bone Effects

In osteoblasts and osteoclasts, raloxifene functions as a partial estrogen agonist, inhibiting bone resorption through suppression of osteoclast differentiation and activity. This effect is mediated through regulation of cytokines involved in osteoclastogenesis, including RANKL, osteoprotegerin (OPG), and interleukin-6. Raloxifene increases the OPG/RANKL ratio, shifting the balance away from bone resorption and toward preservation of bone mass.

Breast Tissue Effects

In breast epithelial cells, raloxifene acts as a pure estrogen antagonist, blocking estrogen-driven proliferation and inhibiting the expression of estrogen-responsive genes involved in cell cycle progression. This anti-estrogenic activity in breast tissue underlies its efficacy in reducing invasive breast cancer incidence, particularly for estrogen receptor-positive tumors.

Research Summary

MORE Trial (Multiple Outcomes of Raloxifene Evaluation)

The MORE trial (1999), published in JAMA, was a pivotal multicenter, randomized, double-blind, placebo-controlled trial that enrolled 7,705 postmenopausal women with osteoporosis. Over 3 years, raloxifene 60 mg daily reduced the risk of vertebral fractures by 30% (RR 0.70, 95% CI 0.56-0.86) and the risk of invasive breast cancer by 72% (RR 0.28, 95% CI 0.17-0.46). This unexpected finding of breast cancer risk reduction became a primary driver of subsequent research into raloxifene’s chemopreventive potential.

Cummings et al. (1999) – Breast Cancer Risk Reduction

Cummings et al. (1999), reporting secondary endpoints from the MORE trial in JAMA, provided the first robust evidence that raloxifene significantly reduced the incidence of estrogen receptor-positive invasive breast cancer by 90% (RR 0.10, 95% CI 0.04-0.24) compared to placebo. This dramatic reduction was specific to ER-positive tumors, with no significant effect on ER-negative breast cancer, consistent with raloxifene’s mechanism as an estrogen receptor antagonist in breast tissue.

STAR Trial (Study of Tamoxifen and Raloxifene)

The NSABP STAR trial (P-2), reported by Vogel et al. (2006) in JAMA, directly compared raloxifene to tamoxifen for breast cancer risk reduction in 19,747 high-risk postmenopausal women. Raloxifene was shown to be as effective as tamoxifen in reducing invasive breast cancer risk (RR 1.02, 95% CI 0.82-1.28) while demonstrating significantly fewer thromboembolic events and cataracts, and critically, no increase in endometrial cancer risk (a known concern with tamoxifen).

Dosing in Published Research

Raloxifene is an FDA-approved prescription medicine, sold as Evista. According to the FDA-approved labeling, the dose for both the prevention and the treatment of postmenopausal osteoporosis is 60 mg once daily, taken at any time of day with or without food, alongside adequate calcium and vitamin D intake. The 60 mg dose was the dose evaluated in the pivotal MORE osteoporosis trial. These figures are drawn from FDA-approved prescribing information.

Safety and Side Effects

Raloxifene is an FDA-approved drug, and it carries an FDA boxed warning, the agency’s most serious warning category. The boxed warning addresses two serious risks: an increased risk of venous thromboembolism, meaning deep vein thrombosis and pulmonary embolism, and an increased risk of death due to stroke in women with documented coronary heart disease or at increased risk for major coronary events. For this reason raloxifene is contraindicated in women with a history of venous thromboembolic events. The most common adverse effects are hot flashes and leg cramps. Because of the thrombosis risk, the drug is generally stopped before and during prolonged immobilization, such as around surgery.

Current Research Status

Raloxifene is an FDA-approved prescription medication, marketed as Evista, approved for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer in certain postmenopausal women. As a prescription drug with a boxed warning, it should be used only under medical supervision and after individual assessment of cardiovascular and thrombosis risk.

Further reading: For a related SERM studied in the context of testosterone support, see Enclomiphene: The SERM Studied for Testosterone.

Frequently Asked Questions